Vasculitis Trial, Recruiting NCT07491913 Sponsor: Marmara University Condition: Vasculitis
Back to Vasculitis

Vasculitis Trial, Recruiting

NCT07491913
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Takayasu arteritis based on the 2022 American College of Rheumatology/EULAR classification criteria
  • People who have been receiving a biologic medication (specifically a TNF inhibitor or tocilizumab) for at least 3 years
  • People whose disease has been in remission, meaning no signs of active disease based on symptoms, blood tests, and imaging
  • People whose treatment has not changed in the past 12 months
  • People who have not taken steroid medications (such as prednisone or cortisone) in the past 6 months
  • People who are willing and able to sign a written consent form agreeing to take part

Who may not be able to join:

  • People who have another active inflammatory condition (such as inflammatory bowel disease or ankylosing spondylitis) that also requires biologic treatment
  • People who would be unable to attend the required follow-up appointments after their medication is gradually reduced or stopped
  • People who are pregnant or planning to become pregnant during the study period

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Fatma Alibaz-Oner, MD, Marmara University

Phone: 05326368554

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Marmara University
Registry
ClinicalTrials.gov
Start date
15 June 2025
Est. completion
15 December 2027

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Proportion of Patients Maintaining Remission After Biologic Treatment Withdrawal

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov